Investigating the role of a specific potassium channel in heart disease
Cell-specific role and therapeutic potential of KCa3.1 in atherosclerosis
This study is looking at how a specific potassium channel might influence the buildup of plaque in the arteries, which can lead to heart disease, and it aims to find out if blocking this channel can help reduce plaque size and improve heart health for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11049061 on NIH RePORTER |
What this research studies
This research focuses on understanding how a potassium channel, KCa3.1, affects the formation and composition of atherosclerotic lesions in coronary artery disease. By studying both genetic and pharmacological methods to block this channel, the researchers aim to determine its role in the migration of smooth muscle and macrophages, which are key players in plaque development. The research utilizes a large mammal model to assess the potential therapeutic effects of existing KCa3.1 inhibitors on reducing lesion size and improving plaque composition. Patients may benefit from insights that could lead to new treatments for heart disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for coronary artery disease, particularly those with a history of acute coronary syndromes.
Not a fit: Patients with stable coronary artery disease who do not exhibit significant plaque formation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for reducing the risk of heart attacks by targeting a specific potassium channel involved in plaque formation.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for cardiovascular disease treatment, suggesting potential for success in this approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Bowles, Douglas K — University of Missouri-Columbia
- Study coordinator: Bowles, Douglas K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.